Amarin Corp Plc (AMRN)

[Dancing in the dark]

if MARINE labeling represents ~5%? of vascepa revenues, how about this?

amarin settles with generics by paying a royalty to generics based upon vascepa Rx's written for triglyercide-lowering effect for patients with trigs over 500 for 12 weeks from Rx start. after 12 weeks, the indication is automatically considered to transition from MARINE indication to REDUCE-IT indication.

instead of paying generics some enormous upfront settlement, let them partake in vascepa's ongoing success, but in a mutually agreed fashion.

vascepa, as so many here have said prior to this patent disaster, is destined to be one of the highest selling drugs of all time.

generics need only determine how to split the royalty revenue amongst themselves.